Phosphodiesterases in neurodegenerative disorders

IUBMB Life

Volumn 64, Issue 12, 2012, Pages 965-970

  Bollen, Eva ^a   Prickaerts, Jos ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Alzheimer's disease; cyclic nucleotides; depression; Huntington's disease; neurodegeneration; phosphodiesterases

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; E1A ASSOCIATED P300 PROTEIN; MESSENGER RNA;

ALZHEIMER DISEASE; AUTOSOMAL DOMINANT INHERITANCE; BRAIN; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; ENZYME INHIBITION; GENETIC DISORDER; HUMAN; HUNTINGTON CHOREA; MAJOR DEPRESSION; MULTIPLE SCLEROSIS; NERVE CELL; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; 3',5'-CYCLIC-GMP PHOSPHODIESTERASES; BRAIN; CYCLIC AMP; CYCLIC GMP; GENE EXPRESSION REGULATION; HUMANS; ISOENZYMES; NEURODEGENERATIVE DISEASES; NEURONS; SIGNAL TRANSDUCTION;

EID: 84870171600     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1104     Document Type: Review

References (71)

1. Francis, S. H., Blount, M. A., and, Corbin, J. D., (2011) Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol. Rev. 91, 651-690.
2. Conti, M., and, Beavo, J., (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 76, 481-511.
3. Bender, A. T., and, Beavo, J. A., (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58, 488-520. (Pubitemid 44394910)
4. Cui, Q., and, So, K. F., (2004) Involvement of cAMP in neuronal survival and axonal regeneration. Anat. Sci. Int. 79, 209-212. (Pubitemid 40017306)
5. Lu, Y. F., and, Hawkins, R. D., (2002) Ryanodine receptors contribute to cGMP-induced late-phase LTP and CREB phosphorylation in the hippocampus. J. Neurophysiol. 88, 1270-1278. (Pubitemid 35025381)
6. Merz, K., Herold, S., and, Lie, D. C., (2011) CREB in adult neurogenesis-master and partner in the development of adult-born neurons? Eur. J. Neurosci. 33, 1078-1086.
7. Jancic, D., Lopez de Armentia, M., Valor, L. M., Olivares, R., and, Barco, A., (2009) Inhibition of cAMP response element-binding protein reduces neuronal excitability and plasticity, and triggers neurodegeneration. Cereb. Cortex 19, 2535-2547.
8. Doronzo, G., Viretto, M., Russo, I., Mattiello, L., Di Martino, L., et al. (2011) Nitric oxide activates PI3-K and MAPK signalling pathways in human and rat vascular smooth muscle cells: influence of insulin resistance and oxidative stress. Atherosclerosis 216, 44-53.
9. Bonni, A., Brunet, A., West, A. E., Datta, S. R., Takasu, M. A., et al. (1999) Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286, 1358-1362.
10. Boucher, M. J., Morisset, J., Vachon, P. H., Reed, J. C., Laine, J., et al. (2000) MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J. Cell. Biochem. 79, 355-369.
11. Jin, K., Mao, X. O., Zhu, Y., and, Greenberg, D. A., (2002) MEK and ERK protect hypoxic cortical neurons via phosphorylation of Bad. J. Neurochem. 80, 119-125. (Pubitemid 34614584)
12. Brunet, A., Datta, S. R., and, Greenberg, M. E., (2001) Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr. Opin. Neurobiol. 11, 297-305. (Pubitemid 32524094)
13. Meyer-Franke, A., Wilkinson, G. A., Kruttgen, A., Hu, M., Munro, E., et al. (1998) Depolarization and cAMP elevation rapidly recruit TrkB to the plasma membrane of CNS neurons. Neuron 21, 681-693. (Pubitemid 28498778)
14. Chen, R. W., Williams, A. J., Liao, Z., Yao, C., Tortella, F. C., et al. (2007) Broad spectrum neuroprotection profile of phosphodiesterase inhibitors as related to modulation of cell-cycle elements and caspase-3 activation. Neurosci. Lett. 418, 165-169. (Pubitemid 46636000)
15. Nakamizo, T., Kawamata, J., Yoshida, K., Kawai, Y., Kanki, R., et al. (2003) Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons. J. Neurosci. Res. 71, 485-495. (Pubitemid 36158332)
16. Urushitani, M., Inoue, R., Nakamizo, T., Sawada, H., Shibasaki, H., et al. (2000) Neuroprotective effect of cyclic GMP against radical-induced toxicity in cultured spinal motor neurons. J. Neurosci. Res. 61, 443-448. (Pubitemid 30620229)
17. Neumann, S., Bradke, F., Tessier-Lavigne, M., and, Basbaum, A. I., (2002) Regeneration of sensory axons within the injured spinal cord induced by intraganglionic cAMP elevation. Neuron 34, 885-893. (Pubitemid 34722279)
18. Nikulina, E., Tidwell, J. L., Dai, H. N., Bregman, B. S., and, Filbin, M. T., (2004) The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. Proc. Natl. Acad. Sci. USA 101, 8786-8790. (Pubitemid 38745849)
19. Qiu, J., Cai, D., Dai, H., McAtee, M., Hoffman, P. N., et al. (2002) Spinal axon regeneration induced by elevation of cyclic AMP. Neuron 34, 895-903. (Pubitemid 34722280)
20. Tanaka, Y., Tanaka, R., Liu, M., Hattori, N., and, Urabe, T., (2010) Cilostazol attenuates ischemic brain injury and enhances neurogenesis in the subventricular zone of adult mice after transient focal cerebral ischemia. Neuroscience 171, 1367-1376.
21. Zhang, R., Wang, Y., Zhang, L., Zhang, Z., Tsang, W., et al. (2002) Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 33, 2675-2680. (Pubitemid 35266440)
22. Ding, G., Jiang, Q., Li, L., Zhang, L., Zhang, Z. G., et al. (2008) Magnetic resonance imaging investigation of axonal remodeling and angiogenesis after embolic stroke in sildenafil-treated rats. J. Cereb. Blood Flow Metab. 28, 1440-1448.
23. Zhang, L., Zhang, R. L., Wang, Y., Zhang, C., Zhang, Z. G., et al. (2005) Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor. Stroke 36, 847-852.
24. Menniti, F. S., Faraci, W. S., and, Schmidt, C. J., (2006) Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discov. 5, 660-670. (Pubitemid 44151604)
25. Shi, J., Qian, W., Yin, X., Iqbal, K., Grundke-Iqbal, I., et al. (2011) Cyclic AMP-dependent protein kinase regulates the alternative splicing of tau exon 10: a mechanism involved in tau pathology of Alzheimer disease. J. Biol. Chem. 286, 14639-14648.
26. Hanger, D. P., Anderton, B. H., and, Noble, W., (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15, 112-119.
27. Bonkale, W. L., Cowburn, R. F., Ohm, T. G., Bogdanovic, N., and, Fastbom, J., (1999) A quantitative autoradiographic study of [3H]cAMP binding to cytosolic and particulate protein kinase A in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits. Brain Res. 818, 383-396. (Pubitemid 29229952)
28. Garcia-Jimenez, A., Cowburn, R. F., Ohm, T. G., Bogdanovic, N., Winblad, B., et al. (1999) Quantitative autoradiography of [3H]forskolin binding sites in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits. Brain Res. 850, 104-117.
29. Liang, Z., Liu, F., Grundke-Iqbal, I., Iqbal, K., and, Gong, C.-X., (2007) Down-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brain. J. Neurochem. 103, 2462-2470. (Pubitemid 350173577)
30. Scott Bitner, R., (2011) Cyclic AMP response element-binding protein (CREB) phosphorylation: a mechanistic marker in the development of memory enhancing Alzheimer's disease therapeutics. Biochem. Pharmacol. 83, 705-714.
31. Perez-Torres, S., Cortes, R., Tolnay, M., Probst, A., Palacios, J. M., et al. (2003) Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization. Exp. Neurol. 182, 322-334. (Pubitemid 36937085)
32. Brun, A., and, Englund, E., (1986) A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann. Neurol. 19, 253-262. (Pubitemid 16111074)
33. McLachlan, C. S., Chen, M. L., Lynex, C. N., Goh, D. L., Brenner, S., et al. (2007) Changes in PDE4D isoforms in the hippocampus of a patient with advanced Alzheimer disease. Arch. Neurol. 64, 456-457. (Pubitemid 46425708)
34. Zhang, H. T., Huang, Y., Suvarna, N. U., Deng, C., Crissman, A. M., et al. (2005) Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats. Psychopharmacology 179, 613-619. (Pubitemid 40674762)
35. Sette, C., and, Conti, M., (1996) Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J. Biol. Chem. 271, 16526-16534. (Pubitemid 26239006)
36. Domek-Lopacinska, K. U., and, Strosznajder, J. B., (2010) Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease. Mol. Neurobiol. 41, 129-137.
37. Blokland, A., Schreiber, R., and, Prickaerts, J., (2006) Improving memory: a role for phosphodiesterases. Curr. Pharm. Des. 12, 2511-2523.
38. Saura, C. A., and, Valero, J., (2011) The role of CREB signaling in Alzheimer's disease and other cognitive disorders. Rev. Neurosci. 22, 153-169.
39. Ciani, E., Guidi, S., Bartesaghi, R., and, Contestabile, A., (2002) Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: implication for a survival role of nitric oxide. J. Neurochem. 82, 1282-1289. (Pubitemid 34966640)
40. Reyes-Irisarri, E., Markerink-Van Ittersum, M., Mengod, G., and, de Vente, J., (2007) Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains. Eur. J. Neurosci. 25, 3332-3338. (Pubitemid 46872773)
41. Boldrini, M., Underwood, M. D., Hen, R., Rosoklija, G. B., Dwork, A. J., et al. (2009) Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology 34, 2376-2389.
42. Bremner, J. D., Narayan, M., Anderson, E. R., Staib, L. H., Miller, H. L., et al. (2000) Hippocampal volume reduction in major depression. Am. J. Psychiatry 157, 115-118.
43. Sheline, Y. I., Gado, M. H., and, Kraemer, H. C., (2003) Untreated depression and hippocampal volume loss. Am. J. Psychiatry 160, 1516-1518. (Pubitemid 41070930)
44. Sheline, Y. I., Wang, P. W., Gado, M. H., Csernansky, J. G., and, Vannier, M. W., (1996) Hippocampal atrophy in recurrent major depression. Proc. Natl. Acad. Sci. USA 93, 3908-3913. (Pubitemid 26144221)
45. Tsopelas, C., Stewart, R., Savva, G. M., Brayne, C., Ince, P., et al. (2011) Neuropathological correlates of late-life depression in older people. Br. J. Psychiatry 198, 109-114.
46. Cowburn, R. F., Marcusson, J. O., Eriksson, A., Wiehager, B., and, O'Neill, C., (1994) Adenylyl cyclase activity and G-protein subunit levels in postmortem frontal cortex of suicide victims. Brain Res. 633, 297-304. (Pubitemid 24021274)
47. Dowlatshahi, D., MacQueen, G. M., Wang, J. F., and, Young, L. T., (1998) Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet 352, 1754-1755. (Pubitemid 28534964)
48. Dwivedi, Y., Conley, R. R., Roberts, R. C., Tamminga, C. A., and, Pandey, G. N., (2002) [(3)H]cAMP binding sites and protein kinase A activity in the prefrontal cortex of suicide victims. Am. J. Psychiatry 159, 66-73. (Pubitemid 41070729)
49. Reiach, J. S., Li, P. P., Warsh, J. J., Kish, S. J., and, Young, L. T., (1999) Reduced adenylyl cyclase immunolabeling and activity in postmortem temporal cortex of depressed suicide victims. J. Affect. Disord. 56, 141-151. (Pubitemid 30058216)
50. Fujita, M., Hines, C. S., Zoghbi, S. S., Mallinger, A. G., Dickstein, L. P., et al. (2012) Downregulation of brain phosphodiesterase type IV measured with (11)C-(R)-rolipram positron emission tomography in major depressive disorder. Biol. Psychiatry 72, 548-554.
51. O'Donnell, J. M., and, Xu, Y., (2012) Evidence for global reduction in brain cyclic adenosine monophosphate signaling in depression. Biol. Psychiatry 72, 524-525.
52. Wong, M. L., Whelan, F., Deloukas, P., Whittaker, P., Delgado, M., et al. (2006) Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc. Natl. Acad. Sci. USA 103, 15124-15129. (Pubitemid 44583175)
53. Luo, H. R., Wu, G. S., Dong, C., Arcos-Burgos, M., Ribeiro, L., et al. (2009) Association of PDE11A global haplotype with major depression and antidepressant drug response. Neuropsychiatr. Dis. Treat. 5, 163-170.
54. Reynolds, R., Roncaroli, F., Nicholas, R., Radotra, B., Gveric, D., et al. (2011) The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol. 122, 155-170.
55. Bopp, T., Becker, C., Klein, M., Klein-Hessling, S., Palmetshofer, A., et al. (2007) Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J. Exp. Med. 204, 1303-1310. (Pubitemid 46919868)
56. Dong, R. P., Umezawa, Y., Ikushima, H., Munakata, Y., Schlossman, S. F., et al. (1997) Different regulatory effects of pentoxifylline on human T cell activation pathways. J. Clin. Immunol. 17, 247-252. (Pubitemid 27261698)
57. Silva, J. C., Rocha, M. F., Lima, A. A., Brito, G. A., de Menezes, D. B., et al. (2000) Effects of pentoxifylline and nabumetone on the serum levels of IL-1β and TNFα in rats with adjuvant arthritis. Inflamm. Res. 49, 14-19. (Pubitemid 30073181)
58. Folcik, V. A., Smith, T., O'Bryant, S., Kawczak, J. A., Zhu, B., et al. (1999) Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors. J. Neuroimmunol. 97, 119-128. (Pubitemid 29301421)
59. Mizrachi, K., Aricha, R., Feferman, T., Kela-Madar, N., Mandel, I., et al. (2010) Involvement of phosphodiesterases in autoimmune diseases. J. Neuroimmunol. 220, 43-51.
60. Vonsattel, J. P., Myers, R. H., Stevens, T. J., Ferrante, R. J., Bird, E. D., et al. (1985) Neuropathological classification of Hungtington's disease. J. Neuropathol. Exp. Neurol. 44, 559-577.
61. Lakics, V., Karran, E. H., and, Boess, F. G., (2010) Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 59, 367-374.
62. Xie, Z., Adamowicz, W. O., Eldred, W. D., Jakowski, A. B., Kleiman, R. J., et al. (2006) Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 139, 597-607.
63. Hebb, A. L., Robertson, H. A., and, Denovan-Wright, E. M., (2004) Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience 123, 967-981. (Pubitemid 38130106)
64. Polli, J. W., and, Kincaid, R. L., (1994) Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. J. Neurosci. 14, 1251-1261.
65. Nishi, A., and, Snyder, G. L., (2010) Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission. J. Pharmacol. Sci. 114, 6-16.
66. Foroud, T., Siemers, E., Kleindorfer, D., Bill, D. J., Hodes, M. E., et al. (1995) Cognitive scores in carriers of Huntington's disease gene compared to noncarriers. Ann. Neurol. 37, 657-664.
67. Lawrence, A. D., Sahakian, B. J., Hodges, J. R., Rosser, A. E., Lange, K. W., et al. (1996) Executive and mnemonic functions in early Huntington's disease. Brain 119, 1633-1645. (Pubitemid 26375733)
68. Lemiere, J., Decruyenaere, M., Evers-Kiebooms, G., Vandenbussche, E., and, Dom, R., (2004) Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation-a longitudinal follow-up study. J. Neurol. 251, 935-942. (Pubitemid 39119311)
69. Giralt, A., Saavedra, A., Carreton, O., Xifro, X., Alberch, J., et al. (2011) Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease. Hum. Mol. Genet. 20, 4232-4247.
70. Kuhlenbaumer, G., Ludemann, P., Schirmacher, A., De Vriendt, E., Hunermund, G., et al. (2004) Autosomal dominant striatal degeneration (ADSD): clinical description and mapping to 5q13-5q14. Neurology 62, 2203-2208. (Pubitemid 38787776)
71. Appenzeller, S., Schirmacher, A., Halfter, H., Baumer, S., Pendziwiat, M., et al. (2010) Autosomal-dominant striatal degeneration is caused by a mutation in the phosphodiesterase 8B gene. Am. J. Hum. Genet. 86, 83-87.